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Background: Thrombocytopenia can result from a wide range of conditions and may be determined by multiple
mechanisms. It can be due to a reduced platelet production or an increased destruction of platelets. Increased
destruction is seen in conditions such as disseminated intravascular coagulation (DIC) and thrombotic
microangiopathies, whereas decreased production is seen in bone marrow (BM) failure syndromes such as aplastic
anemia, myelodysplastic syndromes, and chemotherapy-induced thrombocytopenia. In BM failure syndromes
thrombocytopenia is often accompanied by anemia and/or leucopenia. Recognition of the cause of
thrombocytopenia is often crucial for correct management of patients.
Case presentation: Here, we report on a 71 year-old male caucasian with thrombocytopenia since six years, and a
recent development of anemia. At the time of progression with anemia a bone marrow sampling was done to
examine for a possible causative myeloid malignancy. The morphological examination was normal whereas
immunophenotyping by flowcytometry could not exclude myelodysplasia. Cytogenetic analysis by G-banding
revealed a pericentric inversion of chromosome 2 in 23 out of 25 analyzed metaphases. The inversion was further
characterized by molecular cytogenetics and high-resolution oligo-based array-CGH analysis. Together the analyses
demonstrated a 141.8 Mb pericentric inversion, inv(2)(p23.3q24.3), and concurrent submicroscopic deletions in
2p23.3, 2p22.1, 2q24.3 and 1p13.2 between 0.6-1.9 Mb in size. Locus-specific FISH analyses confirmed all deletions
and the pericentric inversion of chromosome 2. The chromosomal abnormalities were present in 87% of the bone
marrow cells whereas analysis of a skin biopsy revealed a normal male karyotype as well as a normal array-CGH
result. These findings demonstrate that the identified abnormalities were acquired.
Conclusion: To the best of our knowledge, this is the first report of chronic thrombocytopenia and anemia
associated with acquired inv(2)(p23.3q24.3) as a sole cytogenetic abnormality together with concurrent
submicroscopic deletions at 2p23.3, 2p22.1, 2q24.3 and 1p13.2.
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Idiopathic thrombocytopenic purpura (ITP) is a common
hematologic disorder that affects patients of all ages and
with equal sex ratio [1,2]. Primary ITP is defined as iso-
lated thrombocytopenia (platelet count < 100 ×109/L) in
absence of other causes or disorders that may be associ-
ated with thrombocytopenia. Chronic thrombocytopenia
is defined as disease of more than 12 months duration.
Acquired thrombocytopenia may also be part of pancyto-
penia in myelodysplastic syndromes (MDS) or in acute
myeloid leukemia (AML) when either anemia and/or
leucopenia are present [3].
Recognition of the cause of thrombocytopenia is im-
portant for proper treatment of the patients. Cytogenetic
evaluation is a prerequisite in diagnostic work-up of
myeloid malignancies to provide valuable prognostic
information and to determine treatment strategies [4].
Several recurrent cytogenetic abnormalities have been
identified in myeloid malignancies and these have con-
veyed into risk stratification groups [5-8].
In cases with isolated thrombocytopenia cytogenetic
evaluation is uncommon and only few cytogenetic ab-
normalities have been associated with isolated throm-
bocytopenia. Thrombocytopenia-absent radius syndrome
is a rare autosomal recessive disorder that has been asso-
ciated with either RBM8A gene mutation or a 1.35 Mb
microdeletion in 1q21.1 [9,10]. In cases where isolated
thrombocytopenia evolves with additional cytopenias or in
cases where these are present upfront it is suggestive of
possible underlying MDS or AML [3]. In these cases
examination of the bone marrow by morphology, flow
cytometry and cytogenetic analyses are usually performed.
Here is reported the molecular cytogenetic and array-
based CGH characterization of a patient with chronic
thrombocytopenia and anemia without dysplastic signs
or increased blasts in the bone marrow. We identified a
novel acquired pericentric inversion of chromosome 2,
inv(2)(p23.3q24.3), as a sole cytogenetic abnormality
together with four additional concurrent submicroscopic
deletions in 2p23.3, 2p22.1, and 2q24.3 and 1p13.2.




A 71-year old male was referred to our Hematological
Department in January 2013 suspected for MDS. He had
an acute myocardial infarction (AMI) in 1999 and re-
covered from this without complications except for dys-
pnea. He has been on anti-thrombotic medication with
Warfarin and Aspirin since. At the time of referral to our
department he had had thrombocytopenia since 2008
with values between 87–124 × 109/L and developed ad-
ditionally moderate anemia (hemoglobin 7.4 mM) inDecember 2012. His white blood cell counts were in the
years 2008–2013 within normal range whereas he had a
moderate increase in LDH with values between 264–398
U/L. Physical examination revealed areas with bruising of
his skin. He has epistaxis once every second month. He
had been smoking until approximately 6 months prior to
referral with a calculated 10 pack years.
As part of the diagnostic work-up in January 2013 a
bone marrow examination was performed including
morphology and cytogenetic analyses. The morphological
examination was normal whereas the cytogenetics analysis
revealed a pericentric inversion of chromosome 2 in 23
out of 25 analyzed metaphases. Watchful waiting was
decided with additional cytogenetic work-up (se below
for further description). Eighteen month after referral a
follow-up examination of his bone marrow cells included
morphology, flow cytometry and cytogenetic analyses.
Morphology examination was still without dysplastic signs
or increased blasts whereas flow cytometry could not
exclude myelodysplasia. Biochemistry at one-year follow-up
was without progression and showed continued throm-
bocytopenia (platelets, 92 × 109/L) with moderate anemia
(hemoglobin, 7.2 mM). He is continuously well and with-




G-banded chromosomes were prepared after short-term
unstimulated culturing of bone marrow cells, and PHA-
stimulated peripheral blood cells as described [11]. Kar-
yotypes were described according to [12].
Fluorescent in situ hybridization (FISH) analysis
Human multicolor FISH were done according to manu-
facturer’s instructions using the following XCyting multi-
color FISH probes: 1) 24-color karyotyping was done with
the 24Xyte kit consisting of 24 different chromosome
painting probes; and 2) mBanding with XCyte 2 probes
consisting of a series of partial chromosome paint probes
for sequential partially overlapping chromosome regions
of a single chromosome (MetaSystems, Altlussheim,
Germany). Each of the XCyte probes was labeled with one
of five fluorochromes or a unique combination thereof
(combinatorial labeling). Metaphases were counterstained
with 4’,6-diamidino-2-phenylindole (DAPI). Image capture
was done with an automated Zeiss Axio Imager.Z2
equipped with a CCD-camera (CoolCube1) and appro-
priate filters using Isis software (MetaSystems). Karyo-
typing was done using the 24-color mFISH upgrade
package, ISIS, including mBanding.
Whole chromosome painting, chromosome arms specific
painting and locus specific analysis was done with the fol-
lowing directly labeled probes according to manufacturer’s
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chromosome 2 (Kreatech Diagnostics, Amsterdam, The
Netherlands); 2) arms specific painting probes for
chromosome arms 2p and 2q (Kreatech Diagnostics); 3)
LSI ALK dual color, break apart rearrangement probe
(Abbott Molecular, Wiesbaden, Germany); and 4) SE1
(1qh), satellite III probe (Kreatech). Table 1 summarizes
the custom made BAC-based probes (Empire Genomics,
New York, USA) for validating the oaCGH findings. Chro-
mosomes were counterstained with DAPI.
Oligo-based array comparative genomic hybridization
(oaCGH) analysis
oaCGH analysis was performed using CytoChip Cancer
4×180K v2.0 (BlueGnome, Cambridge, UK) encompassing
a 20 kb backbone with highest concentration of probes at
670 cancer genes. The analysis was done according to
manufacturer’s instructions using 0.5 μg patient DNA
from bone marrow cells at initial diagnosis as described in
[11]. After hybridization, washing and drying the oligo
array was scanned at 2.5 μm with GenePix 4400A micro-
array scanner. Initial analysis and normalization was done
with BlueFuseMulti v2.6. For analysis and visualization nor-
malized log2 probe signal values were imported into Nexus
Copy Number software v. 6.1 (BioDiscovery, California,
USA) and segmented using FASST2 segmentation algo-
rithm with a minimum of 3 probes/segment. Regions of
gain or loss contained within copy number variable re-
gions (CNVs) were discarded. Reference genome was
NCBI build 36.1 (hg18). Bioinformatics analysis was per-
formed by querying the UCSC database (http://genome.
ucsc.edu).
Results
G-banding and molecular cytogenetic analysis
Karyotyping by G-banding of unstimulated bone marrow
cells at the time of referral was interpreted as an ap-
parently balanced male karyotype 46,XY, inv(2)(p22q31)
[23]/46,XY[2] showing a predominant pericentric inver-
sion of chromosome 2 (Figure 1A). No additional cryptic
aberrations were revealed after 24-color karyotyping
using the 24XCyte human multicolor (mFISH) probe kitTable 1 Summary of custom made BAC-based probes for
characterization and validation of oaCGH findings







aGenomic positions are given according to NCBI build 36.1 (hg18).(Figure 1B). To more precisely define which chromo-
somal band regions on chromosome 2 that are involved
in the inversion we performed mBanding with the
mBand probe kit XCyte 2. This analysis confirmed the
pericentric inversion and a minor revision of the karyo-
type 46,XY, inv(2)(p23q24)[23]/46,XY[2] could be made
(Figure 2). Analysis of phytohemagglutinin stimulated
cultures of blood lymphocytes also showed the pericen-
tric inversion of chromosome 2 but with less abnormal
metaphases as indicated in the karyotype 46,XY, inv(2)
(p23q24)[2]/46,XY[18]. From this result we could not
determine whether the inv(2) was a constitutional abnor-
mality. For this reason it was decided to perform cyto-
genetic analysis of a skin biopsy, which was done six
months later at the local Department of Clinical Genetics,
and revealed a normal male karyotype. Cytogenetic ana-
lysis of his bone marrow cells at eighteen months follow-
up showed an unchanged abnormal karyotype.
Microarray analysis
To search for possible copy number abnormalities associ-
ated with the pericentric inv(2) we performed oaCGH
analysis using the CytoChip Cancer 4x180K v2.0 (Blue-
Gnome, Cambridge, UK). We used purified DNA from
the bone marrow cells and pooled male DNA as reference.
The oaCGH analysis detected the following copy number
alterations: one microdeletion at 1p13.2 and three micro-
deletions at 2p23.3, 2p22.1 and 2q24.3 (Figure 3A-C).
The microdeletion in chromosome band 1p13.2 has of
maximal size 1,660 kb (pos. 112,954,957-114,615,761;
encompassing the oligonucleotide probes A_14_P134475
to A_16_P152654439) and a minimum size of 1,624 kb
(pos. 112,969,151-114,593,882; encompassing the oligo-
nucleotide probes A_16_P35272698 to A_16_P15265386).
The maximum regions of deletions involved in the other
break point regions are: 1) at chromosome band 2p23.3
the microdeletion encompasses the oligo-nucleotide
probes A_16_P15585250 to A_16_P00335733 mapping
from 23,886,428 to 25,750,824; 2) at chromosome band
2p22.1 the microdeletion encompasses the oligo-nucleotide
probes A_16_P00353846 to A_16_P15623187 mapping
from 38,567,773 to 39,880,865; and 3) at chromosome
band 2q24.3 the microdeletion encompasses the oligo-
nucleotide probes A_16_P35951089 to A_16_P35952722
mapping from 168,830,521 to 169,457,320. The minimum
region of microdeletions involved in the breakpoints are:
1) at chromosome band 2p23.3 the microdeletion encom-
passes the oligo-nucleotide probes A_16_P15585279 to
A_16_P00335710 mapping from 23,897,035 to 25,729,092;
2) at chromosome band 2p22.1 the microdeletion encom-
passes the oligo-nucleotide probes A_16_P15619997 to
A_16_P35646932 mapping from 38,576,675 to 39,859,229;
and 3) at chromosome band 2q24.3 the microdeletion en-
compasses the oligo-nucleotide probes A_16_P00523728
Figure 1 Karyotyping analyses. Panel A. G-banding analysis showed an aberrant karyotype initially interpreted as 46,XY,inv(2)(p22q31)[23]/46,XX
[2]. Panel B. 24-color karyotyping did not reveal any additional cryptic rearrangement. Arrows indicate the aberrant chromosome 2.
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438,394. From these results the respective estimated mini-
mum to maximum deletion sizes are: 1) at 2p23.3: 1,831-
1,864 kb; 2) at 2p22.1: 1,280-1,313 kb; and 3) at 2q24.3:
591–626 kb.
To examine whether the observed microdeletions were
constitutional oaCGH analysis was performed on DNA
purified from the skin biopsy obtained at the time for
karyotyping. The oaCGH analysis was done against pooled
male reference DNA and revealed a normal result, i.e. theFigure 2 mBanding analysis of chromosome 2. The single color gallery
chromosomes arranged in their capture sequence (fluorescein isothiocyana
(7-diethylaminocoumarin-3-carboxylic acid, succinimidyl ester) DEAC, toget
Panel A. Inverted chromosome 2. Panel B. A normal chromosome 2 from t
localization of the different multicolor probes of XCyte 2 relative to the ideobserved microdeletions in the patient’s bone marrow
cells were absent in his skin cells (Figure 3D-F). These
results together with the normal karyotype from his skin
biopsy show that the abnormal inv(2) karyotype with
concurrent microdeletions were confined to the blood
forming tissue and thereby acquired.
Locus-specific FISH analysis
To validate the microdeletion in chromosome 1 band re-
gion p13.2 a locus-specific BAC-based custom-madetool in ISIS software shows individual color schemes of labeled
te) FITC, (spectrum orange) SpO, (texas red) TR, (cyanine 5) Cy5,
her with an inverted grayscale image of the DAPI image (Inv).
he patient’s karyotype. Panel C. A schematic representation of the
ogram of chromosome 2 together with breakpoints marked by arrows.
Figure 3 Genome analysis using high resolution 180 K oligo-based array CGH analysis. Panels A-C. aCGH analysis of DNA from bone
marrow at the time of referral. Panels D-F. aCGH analysis of DNA from a skin biopsy. Vertical blue lines indicate log2 ratios +0.24 and +0.60 and red lines
indicate log2 ratios −0.24 and −1.0. The X-axis at the bottom indicates chromosomal position. Panel A. Whole genome view of the bone marrow
sample showing a total of four submicroscopic deletions at chromosomes 1 and 2 indicated by arrows. Panel B. To the left a chromosome view of
chromosome 1 with deletion at 1p13.2 indicated by an arrow. To the right a zoom view of the deleted region as indicated by red shade together with
its maximal chromosomal position. Panel C. To the left the chromosome view of chromosome 2 with deletions at 2p23.3, 2p22.1 and 2q24.3 as
indicated by arrows. To the right zoom views of the deleted regions as indicated by red shade together with their respective maximal chromosomal
positions. Panel D. Whole genome view of skin biopsy sample lacking the submicroscopic deletions. Panel E. To the left a chromosome view of
chromosome 1 and to the right a zoom view of the same region as in Panel B. Panel F. To the left a chromosome view of chromosome 2 and to the
right a zoom view of the same regions as in Panel C. The relative positions of the different FISH probes used for validation are indicated in different
colors according to the direct fluorescent label used.
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heterochromatic region of chromosome 1q (Figure 4A).
This experiment confirmed the 1p13.2 microdeletion,
which was present in approximately 85% of the bone
marrow cells.
To validate the microdeletions on chromosome 2 locus-
specific FISH analyses were performed using several
BAC-based custom-made probes, which pairwise were co-
hybridized, and compared to dual color chromosome
arms-specific painting probes of chromosome 2. These
experiments showed: 1) the BAC-based probes RP11-
89G5 (2p23.3), RP11-106P6 (2p22.1), and RP11-1104H5
(2q24.3) all exhibited mono-allelic deletions confirming
the microdeletions as suggested by the oaCGH analysis;
and 2) the microdeletions on chromosome 2 are locatedon the same derivative inverted homologue of chromo-
some 2 (Figure 4B). Counting 200 interphase nuclei using
each of the BAC-probes showed that 87-90% of the inter-
phase nuclei contained the microdeletions. Using the
BAC-probe RP11-730G3 (2p23.3), located on the 12.8 Mb
fragment situated between the two microdeletions at
2p23.3 and 2p22.1, and the BAC-probe RP11-937 M17
(2q31.1) it was confirmed that these probes are not in the
deleted regions, as expected from the oaCGH analysis,
and that the probes co-localize as a result of the inv(2)
(Figure 4B). Analyzing 200 interphase nuclei with these
probes the signal pattern 1F1R1G was observed in 85% of
the nuclei and a signal pattern 2R2G in the remaining
15% of the cells confirming that inv(2) is present in ap-
proximately 85% of the cells.
Figure 4 FISH analyses for validation of array findings and a model of the complex chromosomal inversion of chromosome 2. Partial
karyograms of chromosome pair 1 (Panel A) and chromosome pair 2 (Panel B) with the aberrant chromosomes to the left showing FISH results
after hybridization using the respective probes as indicated at the top. The relative positions of the directly labeled RP11-based BAC probes are
indicated in Figure 3. Panel C. Schematic representation of the inversion on chromosome 2 with breakage points indicated by arrows, together
with regions that are deleted and joined. Names of the deleted RP-11-based BAC probes are indicated in red, the moved RP11-730G3 probe is
marked by filled green circles, and the RP11-937M17 is indicated by filled red circles. CAP: chromosome arms-specific painting probes; WCP:
whole chromosome painting probes.
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ALK and t(2;5)(p23;q35)/SQSSTM1-ALK, and inversion
inv(2)(p23q35)/ATIC-ALK involving the ALK gene are
well known rearrangements on chromosome 2 in various
lymphoma types. To examine whether the ALK gene is
involved in our patients inversion 2 rearrangement we
used a commercially available dual color split apart probe
surrounding the ALK gene and show that is not involved
in any translocation or inversion although it is part of the
chromosome 2 segment that is inverted (Figure 4B). Ana-
lyzing 200 interphase nuclei showed a 2F signal pattern in
all examined cells.
Discussion
We have characterized a pericentric inv(2)(p23.3q24.3) in
a patient with chronic thrombocytopenia and moderate
anemia. We identified a 141,8 Mb large inversion with
four concurrent microdeletions which were acquired be-
cause cytogenetic examination and aCGH analysis of a
skin biopsy were normal. The acquired chromosomal inv
(2) is to the best of our knowledge novel as a search inMitelman [13] and literature databases revealed no ad-
ditional cases. In addition, a search in our local registry
with more than 17,000 entries since 2001 was also without
additional cases.
Inversions are considered balanced intrachromosomal
rearrangements formed when a chromosome breaks in
two places and the material between the two breakpoints
reverses orientation before the breaks are sealed. Con-
genital pericentric inversions occur with an estimated
frequency at 0.12-0.70% [14]. Some recurring inversions
are considered normal variants including inversion in
chromosomes 1, 9, and 16 involving the chromosomes
heterochromatic region and in chromosomes 2, 3, 10
and in the Y-chromosome. These chromosomal variants
are often familial and appear to segregate without dele-
terious effect [15].
Acquired inversions are also very rare. In hema-
tological malignancies they are often variants of related
translocations between the two chromosome homo-
logues. The following recurring inversions with their
translocation variants have been described in myeloid
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(11)(p15q22) [18]; and inv(16)(p13q22)/t(16;16)(p13;q22)
[19], and as a result of these rearrangements the fu-
siongenes PSMD2/MECOM, NUP98/DDX10, and CBFB/
MYH11 are formed, respectively. No concurrent sub-
microscopic deletions have been described in these
situations.
Recurrent inversion of chromosome 2 in hema-
tological malignancies has only been described in pa-
tients with anaplastic large cell lymphoma resulting in
the ATIC-ALK fusion gene as a result of inv(2)(p23q35)
[20]. In other cancers, an inv(2)(p21p23)/EML4-ALK,
has been described in non-small cell lung carcinoma
[21]. In our patient we excluded that the ALK gene is in-
volved in the pericentric inversion of chromosome 2
(Figure 4B).
As a result of the pericentric chromosome 2 inversion
in our patient two of the detected microdeletions were at
the inversion break point regions (2p23.3 and 2q24.3) and
an additional in 2p22.1. A model of the inverted chromo-
some 2 is proposed (Figure 4C). This model summarizes
the identified chromosomal events and should not be
viewed as a model describing the order of chromosomal
events. The complex rearrangement of chromosome 2 re-
sults from at least six DNA double-strand breaks (DSBs)
giving rise to seven chromosome 2 fragments of different
sizes. Three of the fragments were deleted as identified by
the BAC-probes RP11-89G5, RP11-106P6 and RP11-
1104H5 while a 12.8 Mb fragment (2p23.3p22.1) harbor-
ing the BAC-probe RP11-730G3 is either directly joined
to the 128.95 Mb large chromosomal fragment encom-
passing the chromosomal bands 2p22.1 to 2q24.3 or it is
inverted before it is joined to this fragment. The most
likely interpretation is that the 12.8 Mb fragment is joined
directly because the probes RP11-730G3 (2p23.3) and
RP11-937 M17 (2q31.1) are co-localized in a similar way
as the RP11-89G5 and the RP11-730G3, which are only a
few kilobasepairs apart (Figure 4B). Finally, this now 141.8
Mb large centromere containing fragment is inverted and
joined to the remaining two distal chromosomal frag-
ments. In silico analysis of the involved chromosomal re-
gions was performed by quering the UCSC database
(http://genome.ucsc.edu) but gave no indications of pos-
sible fusion genes in our inv(2) patient disregarding
possible long range genomic effects as a result of the
rearrangements.
Chromosomal rearrangements are termed “complex”
when a rearrangement involves more than two DNA
strand breaks [22]. The mechanisms responsible for the
development of complex chromosomal rearrangements
remain unclear. According to a recently proposed model
it is suggested that complex rearrangements might result
from a single catastrophic event called “chromothripsis”
as opposed to a progressive model with sequentialaccumulation of chromosomal aberrations [23]. In the
chromothripsis model one or a few chromosomes or
chromosomal regions shatter into tens to hundreds of
pieces in a single event. Some of these pieces are hap-
hazardly stitched together by the DNA repair machinery;
while some pieces are lost resulting in severe localized
complex chromosomal aberrations. Although neither of
the two mechanisms seamlessly can explain the observed
abnormalities of chromosome 2 in our patient it is most
likely that the rearrangements occurred in a single event.
It might be speculated that they result from DSBs
formed from collapsed replication forks because over-
initiation of replication has been identified in pre-
cancerous cells that lead to collapse of replication forks
[24,25]. Recently, it was uncovered that break-induced
replication (BIR) is a DSB repair mechanism capable of
recovering collapsed replication forks at the expense of
producing genomic rearrangements with high frequen-
cies, reviewed in [26]. BIR has also been suggested to be
involved in chromothripsis.
A total of 104 RefSeq genes were deleted as a result of
the submicroscopic deletions detected in our patient: 1)
38 RefSeq genes were deleted in 1p13.2; 2) 34 RefSeq
genes were deleted in 2p23.3; 3) 25 RefSeq genes were
deleted in 2p22.1; and 4) 7 RefSeq genes were deleted in
2q24.3 (Additional file 1: Table S1 for details).
In general, the products of the involved genes in the
described microdeletions are mainly associated with
signal transduction, cytoskeleton organization, transcrip-
tion regulation and mRNA processing. There are, how-
ever, some genes in these regions that attract specific
attention. Interestingly, the DNMT3A gene located in
the deleted region at 2p23.3 is one of the major de novo
methyltransferases in human cells. It is together with
DNMT3B required for development during early em-
bryogenesis and deletion of these genes is embryonic
and perinatal lethal [27]. The DNMT3A gene has been
implicated as one possible mediator of aberrant promo-
tor methylation contributing to the hematopoietic dis-
turbances in MDS [28]. In an in vivo model DNMT3A
loss-of-function confers a preleukemic phenotype on
murine hematopoietic stem cells [29]. The gene ST7L
located at 1p13.2 is part of the observed deletions in our
inv(2) patient. This gene has been suggested to be a
novel tumor suppressor because its allelic loss has been
implicated in various cancers including myeloid malig-
nancy [30]. The LRIG2 gene is another gene located in
the observed 1p13.2 deletion in our patient. It is one of
three human LRIG genes, LRIG1, LRIG2, and LRIG3,
encoding single pass transmembrane proteins, reviewed
in [31]. The LRIG1 is a negative regulator of growth fac-
tor signaling functioning as a tumor suppressor in mice
models whereas the function of LRIG2 and LRIG3 are
less well defined.
Kjeldsen Molecular Cytogenetics  (2015) 8:7 Page 8 of 9These published findings cannot, however, be directly
translated into determining the effects of the submicro-
scopic deletions in our inv(2) patient. One of the reasons
for this is mainly because the patient has more than 100
genes affected by the microdeletions. This observation
might relate to some of the common chromosomal abnor-
malities observed in MDS such as monosomy 5 or large
interstitial deletions on one of the long arms of chromo-
some 5 [32]. In these instances a haploinsufficiency model
has been proposed indicating that loss of a single allele of
more than one gene on 5q may act in concert to alter
hematopoiesis and disrupt normal differentiation [33].
Secondly, we have not examined the expression levels of
the involved genes or determined whether the remaining
alleles might have inactivating mutations.
Despite these facts our present findings might give
some first clues to better understand how chromosomal
and genomic aberrations are related to chronic throm-
bocytopenia with moderate anemia and no clear signs of
MDS. Only few recurrent chromosomal aberrations as-
sociated with isolated congenital thrombocytopenia have
been reported. In the thrombocytopenia-absent radius
syndrome mutations in the RBM8A gene or a 1.35 Mb
microdeletion in 1q21.1 have been linked [9,10], and in
the Paris-Trousseau type thrombocytopenia with dysme-
gakaryopoiesis deletion at chromosome 11 band region
q23 have been reported in several cases [34,35].
In cases where isolated thrombocytopenia evolves with
additional cytopenias or in cases where these present to-
gether it is suggestive of possible underlying MDS or
AML and examination of the bone marrow by mor-
phology, flow cytometry and cytogenetic analyses is
recommended [3].
Conclusions
This study contributes to the identification of cytogen-
etic abnormalities related to thrombocytopenia with
anemia in a patient with an indolent clinical course. It is
the first report of chronic thrombocytopenia and anemia
associated with acquired inv(2)(p23.3q24.3) as a sole
cytogenetic abnormality together with concurrent sub-
microscopic deletions at 2p23.3, 2p22.1, 2q24.3 and
1p13.2. Investigation of similar cases will be necessary to
clarify the clinical significance of the inv(2) and the ob-
served microdeletions.
Even though more than 100 genes are located in the
deleted regions it is possible to evaluate the clinical char-
acteristics in order to further the understanding of their
participation in the pathogenesis, and how genes may
act in concert to alter hematopoiesis and disrupt normal
differentiation.
This study also underlines the necessity to study
hematological patients by different means to get a com-
prehensive picture of the genetic changes in connectionwith acquired disease. G-banding and molecular cyto-
genetics alone would not have identified the concurrent
microdeletions, which were revealed by high-resolution
aCGH analysis. By the aid of custom-made locus-specific
FISH probes it was possible to validate the submicroscopic
deletions as well as to determine more precisely the resul-
tant inversion rearrangement which would not have been
possible by aCGH analysis alone.
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